The present invention relates to inhalations systems for delivering a dose of aerosolized medication from metered-dose inhaler devices, for inhalation by a patient.
Delivery of pharmaceuticals via inhalation has long been considered the standard of care for the treatment patients with acute and chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (“COPD”). Over the past 50 years, metered-dose inhalers (“MDIs”) have become the mainstay of inhaled treatment for such patients. Experience clearly shows that while widely prescribed, many patients cannot or will not use MDIs as intended.
Suboptimal MDI technique contributes to poor lung deposition of medication, poor disease control, adverse asthma and COPD outcomes, and increased medical costs. Studies demonstrate the inability of both patients and healthcare providers to properly use MDIs. Due to the inability of patients to properly use MDIs, a number of devices have been proposed to assist in MDI use. In laboratory test conditions, many devices have appeared to improve MDI aerosol delivery to the lower airways; however, outside of the laboratory, many patients cannot consistently use these devices as intended. Furthermore, for many of the currently available MDI spacer and holding chamber assist devices, it is problematic for the device users to determine if they fully inhale the complete dose following MDI actuation, and difficult for users to master consistent inhalation technique.
Once an MDI canister is triggered, the most important patient centered factors that relate to optimal lung delivery of medication are: (1) initiation of inhalation prior to 80% of total lung capacity (within approximately the first 1-2 seconds after medication is aerosolized), and (2) that the user generate a sufficiently low inspiratory flow rate to effective deliver proper sized aerosol particles into the lung alveoli. The subjective terms “long” or “slowly” are common manufacturer's instruction on MDI medication inserts but these terms have been of little value in ensuring proper patient inhalation technique. Devices which do or not have an effective inspiratory flow signal or fail to provide effective feedback regarding complete dose inhalation may result in medication dosing to the lung that is not constant dose-to-dose or patient-to-patient.
Prior art devices were designed to work with the previous generation of chlorofluorocarbons (“CFC”) MDI devices only. Some of these prior art devices has a built in one size fits all actuator in the mouthpiece. The current hydrofluoroalkane (“HFA”) propellant containing MDIs have a large number of different actuator orifices, so that a single actuator mouthpiece will not adequately function for optimal delivery of the various HFA MDI medications. These prior art devices completely fail to adequately address these elements and do not match optimal characteristics of the inventive device. For example, the prior art devices lack the proper actuator design for proper and efficient MDI particle size generation with current HFA MDI canisters and are designed only for use with prior CFC propellant containing MDIs. Furthermore, many current HFA MDI canisters cannot be used in the prior art devices as the canisters cannot fit into the device mouthpiece, essentially making the device/canister completely non-functional.
Several of the prior art devices lack an inspiratory flow reed and fail to provide any type of signal regarding the users inspiratory flow rate. The inspiratory flow rate is the most critical technique factor which determines the effectiveness of inhaled medication delivery from an MDI canister after the MDI is triggered. Other prior art devices have an inefficiently designed actuator orifice diameter, which produces suboptimal MDI particle size generation, and thus a less efficient device compared to the instant inventive device.
The shortcomings of the prior art devices are that they either lack optimal actuator sizing for the different HFA-MDI formulations, inspiratory flow signal (i.e., not capable of ensuring puff-puff dose equivalency), an easy means for determining if medication is fully inhaled, or have a complicated mechanism presenting difficulty to patients to operate. Manufacturers fail to recognize importance of a properly designed inspiratory flow rate signal for user effective device use and fail to have flow signals which function outside the laboratory for optimal patient use.
Applicant's invention addresses the shortcomings of the prior art by providing a simple, efficient, easy to use device for patients to consistently deliver HFA containing medications from metered-dose inhaler MDIs. Applicant's device insures consistent puff-to-puff delivery of inhaled medications via an adaptor optimized for HFA MDI medications, and an effective inspiratory flow reed signal. The device includes a collapsible bag to which is attached a bidirectional mouthpiece and an adaptor that receives the MDI medication. The mouthpiece contains a reed that functions as an audible signal and a screen to prevent inhalation of unwanted particles. When the MDI is triggered it discharges the medication into the collapsible bag. The medication is inhaled from the collapsible bag, through the mouthpiece, directly into the respiratory tract, collapsing the bag. The reed emits an audible sound if the user inhales above a predetermined rate to maximize medication delivery and ensure dose-to-dose consistency. The user has instant feedback regarding correct inhalation from MDI medication regarding: (1) whether each dose of medication is completely inhaled (the bag fully collapses upon complete inhalation), and (2) whether each dose is inhaled at a rate to achieve efficient lower airway aerosol medication delivery (a whistle sounds of the user breathes in too fast).
Turning first to
The top end cap 28 also has an upstanding collar 36 angularly disposed with respect to the top planar surface of the top end cap 28. There are a pair of vertically disposed keyways 38 cut into the wall of the upstanding collar 36. An MDI adaptor 40 is mounted on the collar 36. There are keys 42 (
A collapsible flexible bag 44 is located below the top end cap 28. The collapsible bag is preferably made from low density polyethylene (“LDPE”) but other similar materials are also available. At the bottom of the LDPE bag 44 is a bottom end cap 46. The top end cap 28 has a circumferential collar that closely receives the top of the LDPE bag 44. The bottom end cap 46 has a similar circumferential collar that receives the bottom of the LDPE bag 44. The fit between the top cap 28 and the bag 44 and the bottom end cap 46 and the bag 44 is snug so that it forms an air tight seal between the caps and the bag.
As seen in
To use the device 20, the mouthpiece 22 is inserted via the locking tabs 34 into slots 32 and rotated to lock the mouthpiece to the top end cap 28. The user inserts an MDI canister into the MDI actuator 58 which aligns it with the MDI adaptor orifice in the top end cap 28. The user opens the bag 44 fully. User then depresses the MDI canister, which then generates flow of medication into the LDPE bag 44. The user inhales through mouthpiece 22, generating negative pressure in bag 44 and causing aerosolized medication to flow into the user's respiratory tract, thereby collapsing the bag 44. The inspiratory flow reed 24 signals if the user inhales above a predetermined flow rate, which is generally above 0.6 liter/sec. After inhalation and 10 second breathhold, the user manually opens and expands the bag 44 to allow for a subsequent MDI actuation cycle. The device 20 provides two indicators if the device is used properly. The first signal is a visual signal that indicates whether the user has fully inhaled the medication. This is indicated by the user seeing if the bag is fully collapsed. The second indicator is an audio signal indicating if the user incorrectly inhaled the medication. This is indicated by the reed in the device emitting a whistling or other audible sound if user inhales too fast for proper medication delivery to the lungs.
Thus there has been provided a delivery device for metered dose inhalers for providing a drug to a user through inhalation that provides for the receipt of various sized MDI canisters. It also provides two indicators for the user to make sure that the full dose of medication is inhaled and that the rate of inhalation is not at a flow rate that exceeds recommended flow rates. While the invention has been described in conjunction with a specific embodiment, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art in light of the foregoing description. Accordingly, it in intended to embrace all such alternatives, modifications and variations as fall within the spirit and scope of the claims
This application is based on and claims the priority of U.S. provisional patent application Ser. No. 62/126,973 filed Mar. 2, 2015.
Number | Date | Country | |
---|---|---|---|
62126973 | Mar 2015 | US |